| 新型降糖药物Exenatide研究进展及前景展望 |
| |
| 引用本文： | 龙娟,刘志敏,杨晓红.新型降糖药物Exenatide研究进展及前景展望[J].生物技术通讯,2008,19(2):286-289. |
| |
| 作者姓名： | 龙娟 刘志敏 杨晓红 |
| |
| 作者单位： | 1. 西南大学,园艺园林学院,重庆,400716;西南大学,园艺园林学院,重庆,400716
2. 西南大学,园艺园林学院,重庆,400716 |
| |
| 摘 要： | Exenatide是胰高血糖素样肽-1（GLP-1）受体的一种激动剂，可模拟人体自身激素GLP-1的功能，具有促进胰腺p-细胞增殖、改善其功能，以及促进胰岛素分泌，增加机体对胰岛素的敏感性和延缓胃排空等作用，因而有着传统治疗糖尿病药物不可比拟的优点，近年来已经成为糖尿病治疗领域的研究热点，应用前景非常广阔。简要介绍了Exenatide的生物活性、作用机理和临床应用现状，并对Exenatide长效降糖方面的研究进行了展望。
|
| 关 键 词： | Exenatide 糖尿病 胰高血糖素样肽-1受体 |
| 文章编号： | 1009-0002(2008)02-0286-04 |
| 修稿时间： | 2007年10月10 |
The Research Actuality and Prospect on Exenatide,a Novel Therapy for Type 2 Diabetes |
| |
| LONG Juan,LIU Zhi-Min,YANG Xiao-Hong.The Research Actuality and Prospect on Exenatide,a Novel Therapy for Type 2 Diabetes[J].Letters in Biotechnology,2008,19(2):286-289. |
| |
| Authors: | LONG Juan LIU Zhi-Min YANG Xiao-Hong |
| |
| Institution: | LONG Juan, LIU Zhi-Min, YANG Xiao-Hong( 1. Beijing Institute of Biotechnology, Beijing 100071; 2. College of Horticulture and Landscape Architecture, Southwest U- niversity, Chongqing 400716; China) |
| |
| Abstract: | Exenatide is a receptor agonist of the insulinotropic gut hormone glucagon-like peptide 1 （GLP-1）,which acts like the naturally occurring hormone GLP-1 in vivo. Its glucoregulatory activities include enhancing glucose-dependent insulin synthesis from pancreatic β-cells, decreasing glucagon production, slowing gastric emptying time, and also it is thought to have beneficial effects on β-cell mass. Lately it has represented an attractive therapeutic principle for diabetes. In this article, its physiological functions, mechanism, status quo, as well as its potential evolution were briefly reviewed. |
| |
| Keywords: | Exenatide diabetes mellitus glucagon-like peptide 1 receptor |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
